Skin - commissioning policies

Please click on the links below to access the commissioning policies. The associated Equality Impact Assessments, if currently available, are accessible here.

The CCGs’ position on the implementation of policies affecting patient referral can be found here.
Benign skin and subcutaneous lesions - assessment and removal
To access the accompanying Clinical policy patient support information for the benign skin lesions policy please click here
Brimonidine gel (Mirvaso®) for the symptomatic treatment of facial erythema of rosacea in adult patients Clindamycin 1%/Tretinoin 0.025% gel (Treclin®) for the topical treatment of acne vulgaris Focal hyperhidrosis Imiquimod 3.75% (Zyclara™) for actinic keratosis Ivermectin 1% cream (Soolantra®) for the treatment of inflammatory lesions of papulopustular rosacea Surgery for ganglion cyst (see surgery commissioning policies, click here)

Please note:  Some commissioning policies approved by the previous commissioning organisations are yet to be reviewed and updated. There is an on-going programme of work in place to review and update these policies. They will then be published under the appropriate category. 

In the meantime they are still applicable to Northern, Eastern and Western Devon CCG. Former NHS Devon policies can be accessed here

Rate this page